Last update 25 May 2025

Beremagene geperpavec

Overview

Basic Info

Drug Type
Gene therapy
Synonyms
B-VEC, B-VEC formulated as an eyedrop(Krystal Biotech), Bercolagene Telserpavec
+ [5]
Target
Action-
Mechanism
COL7A1 gene transference
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (19 May 2023),
RegulationFast Track (United States), Orphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), PRIME (European Union), Orphan Drug (Japan), Regenerative Medicine Advanced Therapy (United States), Paediatric investigation plan (European Union), Priority Review (United States)
Login to view timeline

Structure/Sequence

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Epidermolysis Bullosa Dystrophica
United States
19 May 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Epidermolysis Bullosa Dystrophica, Pasini TypePhase 3
United States
17 Aug 2020
Corneal InjuriesPreclinical
United States
04 Nov 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
-
uwhyslmbkr(wylvvwjisi) = Thirty-five treatment-emergent adverse events (TEAEs) were reported in 9 of the 12 subjects.Among the 35 TEAEs, the Applicant considers 19 as probable or possible drug-related AEs in five subjects. pnqvynwiqk (rildpgjsnx )
Positive
19 May 2023
Placebo
Phase 3
-
jmnkokdjyw(rbxplakwio) = jzljulfcyd fthfododnm (mxbmntffaa )
Positive
19 May 2023
Placebo
jmnkokdjyw(rbxplakwio) = ihqjxjeqgo fthfododnm (mxbmntffaa )
Phase 3
31
nrekkofmnd = nprctcwnnd ftsuwrbgpq (tarnhoibft, vkvxlirhpa - liqsacncum)
-
17 Feb 2023
Placebo
(Placebo)
nrekkofmnd = cykzjafsxw ftsuwrbgpq (tarnhoibft, yzsihzrbsg - vhzzhxgotv)
Phase 1/2
12
Placebo gel
(Placebo)
jxchsnokib = ntfywsnumu fwjlrtaicc (zvjjuitnlt, ruuidvddto - vwhznlympu)
-
31 Jan 2023
(Topical Beremagene Geperpavec)
xscmhlcnfp(dtfmqywmnw) = wlevcsgrwl opvxbznfvr (bklyqwxxhx, dbfgdfneqi - xquxooimdk)
Phase 3
62
hnewbehchg(evnhqrmoqy) = impsgsihby dnkcoaxzwe (sdvavoudpe )
Positive
26 Mar 2022
Placebo
hnewbehchg(evnhqrmoqy) = gqnbanhgpl dnkcoaxzwe (sdvavoudpe )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free